文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT评估免疫器官用于黑色素瘤免疫检查点抑制剂治疗监测

Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-12

该回顾性单中心观察性研究纳入29例晚期黑色素瘤患者,分析基线与治疗中18F-FDG PET/CT的14项免疫器官代谢指标,并与7项生物学标志物和7项临床变量比较。结果显示脾/肝平均SUV比值(SLRmean)可重复性好,其3个月时较基线升高超过25%与免疫检查点抑制剂治疗后预后不良相关。

要点

  • SLRmean重复性良好(ICC 0.86),可作为免疫治疗预后指标。
  • SLRmean 3个月较基线升高>25%与ICIs后不良结局相关。
  • 脾长径、脾前部SUVpeak等指标在1年OS组间呈现差异趋势。

核心结论

  • SLRmean被推荐作为接受免疫治疗的黑色素瘤患者的预后指标。
  • SLRmean在3个月时较基线升高大于25%与ICIs后不良结局相关。

研究设计与样本

  • 回顾性单中心观察性研究,纳入29例接受基线18F-FDG PET/CT的晚期黑色素瘤患者。
  • 患者后续接受治疗1个月后的早期监测PET/CT(iPET)以及第3个月(M3PET)和第6个月(M6PET)的随访检查。
  • 由两名PET阅片者回顾免疫器官(脾、骨髓、回盲瓣)的18F-FDG摄取及衍生的脾/肝比(SLR)和骨/肝比(BLR),共14项PET变量用于可重复性分析。
  • 将可重复性最好的指标与imPERCIST5疗效反应、全身代谢活性肿瘤体积(WB-MATV)及生物学参数比较,评估其作为总生存(OS)预测因素的价值。

主要发现

  • 脾前部SUVpeak、脾MV、脾TLG、脾长径和BLRmean的组内相关系数(ICC)均大于0.90,重复性强。
  • SLRmean和回盲部SUVmean的ICC分别为0.86和0.65。
  • 在1年OS 1组中,SLRmean在各时间点呈升高趋势,至M6-PET达到显著差异(p=0.019)。
  • 在1年OS 0组中,脾长径在iPET时较基线PET显著增加(p=0.014),较M3-PET亦显著增加(p=0.0239)。
  • 单因素Kaplan-Meier生存分析显示,i%var脾长径、M3%var SLRmean、基线LDH、i%var NLR和M6PET疗效反应均为1年OS的预测因素。

关键数值与推荐

  • SLRmean重复性ICC为0.86,回盲部SUVmean的ICC为0.65。
  • 脾前部SUVpeak、脾MV、脾TLG、脾长径和BLRmean的ICC均大于0.90。
  • 1年OS 1组中SLRmean在M6-PET较基线差异显著(p=0.019)。
  • 1年OS 0组中脾长径在iPET较基线显著增加(p=0.014),较M3-PET显著增加(p=0.0239)。
  • SLRmean在3个月时较基线升高大于25%与ICIs后不良结局相关。

临床怎么用

  • 可利用18F-FDG PET/CT测量的SLRmean进行免疫治疗患者的预后分层。
  • 建议在基线和治疗3个月时关注SLRmean变化,升高超过25%提示预后不良。
  • 脾长径和脾前部SUVpeak等可重复性好的指标可作为辅助监测参数。

局限性

  • 研究为回顾性单中心观察性设计,样本量29例。
  • 部分指标(如回盲部SUVmean)重复性中等(ICC 0.65)。
  • SLRmean升高大于25%的阈值需在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma. There is a need for robust biomarkers to identify patients who do not respond. We analysed 14 baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) metrics and their evolution to assess their correlation with patient outcome, compared with 7 established biological markers and 7 clinical variables. METHODS: We conducted a retrospective monocentric observational study of 29 patients with advanced melanoma who underwent baseline 18F-FDG PET/CT, followed by an early monitoring PET/CT (iPET) scan after 1 month of treatment and follow-up studies at 3rd (M3PET) and 6th month (M6PET). 18F-FDG uptake in immune organs (spleen, bone marrow, ileocecal valve) and derived spleen-to-liver (SLR) and bone-to-liver (BLR) ratios were reviewed by two PET readers for reproducibility analysis purposes including 14 PET variables. The most reproducible indexes were used for evaluation as predictors of overall survival (OS) in comparison with PET response using imPERCIST5, whole-body metabolic active tumour volume (WB-MATV) and biological parameters (lactate dehydrogenases (LDH), reactive protein c (CRP), white blood count (WBC), absolute lymphocyte count (ALC), neutrophil to lymphocyte ratio (NLR) and derived neutrophils to lymphocyte ratio). RESULTS: Strong reproducibility's (intraclass coefficients of correlation (ICC) > 0.90) were observed for spleen anterior SUVpeak, spleen MV, spleen TLG, spleen length and BLRmean. ICC for SLRmean and ileocecal SUVmean were 0.86 and 0.65, respectively. In the 1-year OS 1 group, SLRmean tended to increase at each time point to reach a significant difference at M6-PET (p = 0.019). The same trends were observed with spleen SUVpeak anterior and spleen length. In the 1-year OS 0 group, a significative increase of spleen length was found at iPET, as compared with baseline PET (p = 0.014) and M3-PET (p = 0.0239). Univariable Kaplan-Meier survival analysis found that i%var spleen length, M3%var SLRmean, baseline LDH, i%var NLR and response at M6PET were all predictors of 1-year OS. CONCLUSIONS: SLRmean is recommended as a prognosticator in melanoma patients under immunotherapy: its increase greater than 25% at 3 months, compared with baseline, was associated with poor outcome after ICIs.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Prigent K, Lasnon C, Ezine E, et al. Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 33432374. doi:10.1007/s00259-020-05103-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。